Impact of the Major Candida glabrata Triazole Resistance Determinants on the Activity of the Novel Investigational Tetrazoles VT-1598 and VT-1161

VT-1161 and VT-1598 are promising investigational tetrazole antifungals that have shown in vitro and in vivo activity against Candida and other fungi. Candida glabrata is a problematic opportunistic pathogen that is associated with high mortality in invasive infection, as well as both intrinsic and rapidly acquired antifungal resistance. ABSTRACT VT-1161 and VT-1598 are promising investigational tetrazole antifungals that have shown in vitro and in vivo activity against Candida and other fungi. Candida glabrata is a problematic opportunistic pathogen that is associated with high mortality in invasive infection, as well as both intrinsic and rapidly acquired antifungal resistance. The MICs of VT-1161 and VT-1598 were determined by CLSI methodology to evaluate their in vitro activities against clinical C. glabrata isolates and strains containing individual deletions of the zinc cluster transcription factor genes PDR1 and UPC2A as well as the efflux transporter genes CDR1, PDH1, and SNQ2. Overall, both tetrazoles demonstrated relative activities comparable to those of the tested triazole antifungals against clinical C. glabrata isolates (MIC range, 0.25 to 2 mg/liter and 0.5 to 2 μg/ml for VT-1161 and VT-1598, respectively). Deletion of the PDR1 gene in fluconazole-resistant matched clinical isolate SM3 abolished the decreased susceptibility phenotype completely for both VT-1161 and VT-1598, similarly to the triazoles. UPC2A deletion also increased susceptibility to both triazoles and tetrazoles but to a lesser extent than PDR1 deletion. Of the three major transporter genes regulated by Pdr1, CDR1 deletion resulted in the largest MIC reductions for all agents tested, while PDH1 and SNQ2 deletion individually impacted MICs very little. Overall, both VT-1161 and VT-1598 have comparable activities to those of the available triazoles, and decreased susceptibility to these tetrazoles in C. glabrata is driven by many of the same known resistance mechanisms.

[1]  J. Bohlius,et al.  Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[2]  S. Kelly,et al.  In Vitro Activities of the Novel Investigational Tetrazoles VT-1161 and VT-1598 Compared to the Triazole Antifungals against Azole-Resistant Strains and Clinical Isolates of Candida albicans , 2019, Antimicrobial Agents and Chemotherapy.

[3]  J. Tyndall,et al.  Azole Resistance Reduces Susceptibility to the Tetrazole Antifungal VT-1161 , 2018, Antimicrobial Agents and Chemotherapy.

[4]  R. Lynfield,et al.  Changes in Prevalence of Health Care–Associated Infections in U.S. Hospitals , 2018, The New England journal of medicine.

[5]  Christina M. Henderson,et al.  VT-1598 inhibits the in vitro growth of mucosal Candida strains and protects against fluconazole-susceptible and -resistant oral candidiasis in IL-17 signalling-deficient mice , 2018, The Journal of antimicrobial chemotherapy.

[6]  P. D. Rogers,et al.  Relative Contribution of the ABC Transporters Cdr1, Pdh1, and Snq2 to Azole Resistance in Candida glabrata , 2018, Antimicrobial Agents and Chemotherapy.

[7]  E. Garvey,et al.  The novel fungal CYP51 inhibitor VT-1598 is efficacious alone and in combination with liposomal amphotericin B in a murine model of cryptococcal meningitis , 2018, The Journal of antimicrobial chemotherapy.

[8]  P. Nyirjesy,et al.  A phase 2, randomized, double‐blind, placebo‐controlled, dose‐ranging study to evaluate the efficacy and safety of orally administered VT‐1161 in the treatment of recurrent vulvovaginal candidiasis , 2018, American journal of obstetrics and gynecology.

[9]  E. Garvey,et al.  The Novel Fungal Cyp51 Inhibitor VT-1598 Is Efficacious in Experimental Models of Central Nervous System Coccidioidomycosis Caused by Coccidioides posadasii and Coccidioides immitis , 2018, Antimicrobial Agents and Chemotherapy.

[10]  E. Garvey,et al.  Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus , 2018, The Journal of antimicrobial chemotherapy.

[11]  T. Calandra,et al.  Changes in the epidemiological landscape of invasive candidiasis , 2018, The Journal of antimicrobial chemotherapy.

[12]  E. Garvey,et al.  Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors. , 2017, Bioorganic & medicinal chemistry letters.

[13]  Z. Wawrzak,et al.  Crystal Structure of the New Investigational Drug Candidate VT-1598 in Complex with Aspergillus fumigatus Sterol 14α-Demethylase Provides Insights into Its Broad-Spectrum Antifungal Activity , 2017, Antimicrobial Agents and Chemotherapy.

[14]  E. Berkow,et al.  Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species , 2017, Frontiers in microbiology.

[15]  P. D. Rogers,et al.  Azole Resistance in Candida glabrata , 2016, Current Infectious Disease Reports.

[16]  J. Sobel,et al.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  O. Cornely,et al.  Candida glabrata – unique features and challenges in the clinical management of invasive infections , 2015, Mycoses.

[18]  J. Sobel,et al.  Efficacy of the Clinical Agent VT-1161 against Fluconazole-Sensitive and -Resistant Candida albicans in a Murine Model of Vaginal Candidiasis , 2015, Antimicrobial Agents and Chemotherapy.

[19]  Ronald N. Jones,et al.  Regional data analysis of Candida non‐albicans strains collected in United States medical sites over a 6‐year period, 2006–2011 , 2014, Mycoses.

[20]  D. Kelly,et al.  The Clinical Candidate VT-1161 Is a Highly Potent Inhibitor of Candida albicans CYP51 but Fails To Bind the Human Enzyme , 2014, Antimicrobial Agents and Chemotherapy.

[21]  E. Garvey,et al.  Design and optimization of highly-selective fungal CYP51 inhibitors. , 2014, Bioorganic & medicinal chemistry letters.

[22]  S. G. Chadwick,et al.  UPC2A Is Required for High-Level Azole Antifungal Resistance in Candida glabrata , 2014, Antimicrobial Agents and Chemotherapy.

[23]  L. Harrison,et al.  Species Identification and Antifungal Susceptibility Testing of Candida Bloodstream Isolates from Population-Based Surveillance Studies in Two U.S. Cities from 2008 to 2011 , 2012, Journal of Clinical Microbiology.

[24]  D. Horn,et al.  The PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: update 2012. , 2012, Diagnostic microbiology and infectious disease.

[25]  M. Ghannoum,et al.  Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. , 2011, Diagnostic microbiology and infectious disease.

[26]  Ramin Homayouni,et al.  Genomewide Expression Profile Analysis of the Candida glabrata Pdr1 Regulon , 2010, Eukaryotic Cell.

[27]  J. Sobel Changing trends in the epidemiology of Candida blood stream infections: a matter for concern? , 2010, Critical care medicine.

[28]  A. Rodloff,et al.  Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-Year Analysis of Susceptibilities of Candida Species to Fluconazole and Voriconazole as Determined by CLSI Standardized Disk Diffusion , 2010, Journal of Clinical Microbiology.

[29]  G. Fadda,et al.  The ATP‐binding cassette transporter–encoding gene CgSNQ2 is contributing to the CgPDR1‐dependent azole resistance of Candida glabrata , 2008, Molecular microbiology.

[30]  Clinical,et al.  Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard , 2008 .

[31]  R. Homayouni,et al.  Pdr1 regulates multidrug resistance in Candida glabrata: gene disruption and genome‐wide expression studies , 2006, Molecular microbiology.

[32]  J. Bennett,et al.  Candida glabrata PDR1, a Transcriptional Regulator of a Pleiotropic Drug Resistance Network, Mediates Azole Resistance in Clinical Isolates and Petite Mutants , 2006, Antimicrobial Agents and Chemotherapy.

[33]  M. Choti,et al.  Triazole Cross-Resistance among Candida spp.: Case Report, Occurrence among Bloodstream Isolates, and Implications for Antifungal Therapy , 2006, Journal of Clinical Microbiology.

[34]  B. Arthington-Skaggs,et al.  Rapid Acquisition of Stable Azole Resistance by Candida glabrata Isolates Obtained before the Clinical Introduction of Fluconazole , 2005, Antimicrobial Agents and Chemotherapy.

[35]  G. Fadda,et al.  Mechanisms of Azole Resistance in Clinical Isolates of Candida glabrata Collected during a Hospital Survey of Antifungal Resistance , 2005, Antimicrobial Agents and Chemotherapy.

[36]  R. Kolter,et al.  The SAT1 flipper, an optimized tool for gene disruption in Candida albicans. , 2004, Gene.

[37]  T. Edlind,et al.  Azole Resistance in Candida glabrata: Coordinate Upregulation of Multidrug Transporters and Evidence for a Pdr1-Like Transcription Factor , 2004, Antimicrobial Agents and Chemotherapy.

[38]  Shane Gillespie,et al.  Attributable mortality of nosocomial candidemia, revisited. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  D. Sanglard,et al.  Role of ATP-Binding-Cassette Transporter Genes in High-Frequency Acquisition of Resistance to Azole Antifungals in Candida glabrata , 2001, Antimicrobial Agents and Chemotherapy.

[40]  D. Sanglard,et al.  The ATP Binding Cassette Transporter GeneCgCDR1 from Candida glabrata Is Involved in the Resistance of Clinical Isolates to Azole Antifungal Agents , 1999, Antimicrobial Agents and Chemotherapy.

[41]  D. Ward,et al.  Fluconazole Resistance Associated with Drug Efflux and Increased Transcription of a Drug Transporter Gene, PDH1, inCandida glabrata , 1998, Antimicrobial Agents and Chemotherapy.